The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.